HK1126412A1 - Crystalline pyrimidine nucleoside derivatives suspensions in capsules - Google Patents

Crystalline pyrimidine nucleoside derivatives suspensions in capsules

Info

Publication number
HK1126412A1
HK1126412A1 HK09105247.1A HK09105247A HK1126412A1 HK 1126412 A1 HK1126412 A1 HK 1126412A1 HK 09105247 A HK09105247 A HK 09105247A HK 1126412 A1 HK1126412 A1 HK 1126412A1
Authority
HK
Hong Kong
Prior art keywords
capsules
suspensions
pyrimidine nucleoside
nucleoside derivatives
crystalline pyrimidine
Prior art date
Application number
HK09105247.1A
Other languages
English (en)
Inventor
Robert Westwood
Alistair Selkirk
Original Assignee
Cyclacel Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cyclacel Ltd filed Critical Cyclacel Ltd
Publication of HK1126412A1 publication Critical patent/HK1126412A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
HK09105247.1A 2005-12-23 2009-06-11 Crystalline pyrimidine nucleoside derivatives suspensions in capsules HK1126412A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0526419.7A GB0526419D0 (en) 2005-12-23 2005-12-23 Formulation
PCT/GB2006/004927 WO2007072061A2 (fr) 2005-12-23 2006-12-22 Formulation

Publications (1)

Publication Number Publication Date
HK1126412A1 true HK1126412A1 (en) 2009-09-04

Family

ID=35841215

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09105247.1A HK1126412A1 (en) 2005-12-23 2009-06-11 Crystalline pyrimidine nucleoside derivatives suspensions in capsules

Country Status (17)

Country Link
US (1) US8497291B2 (fr)
EP (1) EP1962814B1 (fr)
JP (2) JP5443763B2 (fr)
CN (1) CN101346132B (fr)
AU (1) AU2006327951B2 (fr)
BR (1) BRPI0620229B8 (fr)
CA (1) CA2633308C (fr)
DK (1) DK1962814T3 (fr)
ES (1) ES2672106T3 (fr)
GB (1) GB0526419D0 (fr)
HK (1) HK1126412A1 (fr)
HU (1) HUE039368T2 (fr)
IL (1) IL192348A (fr)
PT (1) PT1962814T (fr)
RU (1) RU2428972C2 (fr)
TR (1) TR201808182T4 (fr)
WO (1) WO2007072061A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1302007C (zh) 2001-04-30 2007-02-28 葛兰素集团有限公司 具有抗炎性的在17.α位上具有环酯基的雄甾烷的17.β.－硫代羧酸酯衍生物
GB0625283D0 (en) 2006-12-19 2007-01-24 Cyclacel Ltd Combination
EP2148676B1 (fr) * 2007-04-25 2016-05-25 Cyclacel Limited Utilisation de la sapacitabine dans le traitement d'une maladie proliférative
US8124593B2 (en) 2007-11-05 2012-02-28 Cyclacel Limited Methods of treatment using sapacitabine
GB0808357D0 (en) 2008-05-08 2008-06-18 Cyclacel Ltd Process
CN102088969B (zh) 2008-06-09 2013-06-12 西克拉塞尔有限公司 沙帕他滨或cndac与dna甲基转移酶抑制剂如地西他滨和普鲁卡因的组合
RU2538593C2 (ru) * 2009-05-15 2015-01-10 Дельта-Флай Фарма, Инк. НОВЫЕ СТАБИЛЬНЫЕ КРИСТАЛЛЫ МОНОГИДРОХЛОРИДА 1-(2-β-D-АРАБИНОФУРАНОЗИЛ)ЦИТОЗИНА
JP6209446B2 (ja) 2010-06-02 2017-10-04 アステラス ドイチュランド ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンダムスチンの経口投与形
EP2696878B1 (fr) 2011-04-14 2019-07-10 Cyclacel Limited Régime posologique pour la sapacitabine et la décitabine en association pour le traitement de la leucémie myéloïde aiguë
JP5873375B2 (ja) * 2012-04-03 2016-03-01 中日本カプセル 株式会社 ソフトカプセル及びソフトカプセルの製造方法
JP6286421B2 (ja) 2012-05-15 2018-02-28 サイクラセル リミテッド サパシタビン及びセリシクリブの投与レジメン
EP2961384B1 (fr) * 2013-02-28 2019-08-28 Basf As Composition comprenant un composé lipidique, un triglycéride et un tensioactif, et procédés d'utilisation associés
CN106963742B (zh) * 2016-11-07 2021-02-23 澳门大学 中药固液胶囊及其制备方法
WO2019081951A1 (fr) 2017-10-27 2019-05-02 Cyclacel Limited Régime posologique
WO2021079129A1 (fr) 2019-10-24 2021-04-29 Cyclacel Limited Régime posologique

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2126573T3 (es) * 1991-04-22 1999-04-01 Otsuka Pharma Co Ltd Derivado de pirazol (1,5-a)pirimidina y agente antiinflamatorio que contiene este derivado.
RU2085557C1 (ru) * 1991-09-30 1997-07-27 Санкио Компани Лимитед Производные нуклеозидов пиримидина или их фармацевтически приемлемые соли и способ их получения
DE4322826A1 (de) * 1993-07-08 1995-01-12 Galenik Labor Freiburg Gmbh Pharmazeutisches Präparat
US5599922A (en) * 1994-03-18 1997-02-04 Lynx Therapeutics, Inc. Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
KR19980073479A (ko) * 1997-03-14 1998-11-05 한스루돌프하우스, 니콜케르커 사이클로스포린-함유 연질캅셀제
NL1003503C2 (nl) * 1996-07-04 1998-01-07 Negma Steba International Dev Farmaceutische samenstelling voor orale toediening.
GB9918885D0 (en) * 1999-08-10 1999-10-13 Pharmacia & Upjohn Spa Pharmaceutical formulations in hydroxypropymethycellulose capsules
US6908906B2 (en) * 2001-02-09 2005-06-21 Sankyo Company, Limited Crystalline forms of pyrimidine nucleoside derivative
JP3748536B2 (ja) * 2001-02-09 2006-02-22 三共株式会社 ピリミジンヌクレオシド誘導体の結晶
DE60222803T2 (de) * 2001-12-21 2008-07-17 Supernus Pharmaceuticals, Inc. Orale kapselformulierung mit verbesserter physikalischer stabilität
JP5096658B2 (ja) * 2003-10-06 2012-12-12 株式会社三協 生物学的利用能を向上させたソフトカプセル
US20050249802A1 (en) * 2004-05-06 2005-11-10 The Procter & Gamble Company Softgel encapsulated pharmaceutical compositions comprising concentrated active ingredients
GB0413730D0 (en) 2004-06-18 2004-07-21 Tillotts Pharma Ag A pharmaceutical composition and its use

Also Published As

Publication number Publication date
CA2633308A1 (fr) 2007-06-28
IL192348A0 (en) 2009-08-03
DK1962814T3 (en) 2018-08-06
PT1962814T (pt) 2018-06-22
US20090074856A1 (en) 2009-03-19
WO2007072061A2 (fr) 2007-06-28
GB0526419D0 (en) 2006-02-08
WO2007072061A3 (fr) 2007-10-25
BRPI0620229B1 (pt) 2020-09-15
AU2006327951A1 (en) 2007-06-28
BRPI0620229B8 (pt) 2021-05-25
EP1962814A2 (fr) 2008-09-03
JP5443763B2 (ja) 2014-03-19
CN101346132A (zh) 2009-01-14
JP2013189463A (ja) 2013-09-26
AU2006327951B2 (en) 2012-09-06
HUE039368T2 (hu) 2018-12-28
ES2672106T3 (es) 2018-06-12
JP2009520797A (ja) 2009-05-28
RU2008130411A (ru) 2010-01-27
IL192348A (en) 2016-02-29
CA2633308C (fr) 2014-06-17
CN101346132B (zh) 2013-01-16
EP1962814B1 (fr) 2018-04-25
TR201808182T4 (tr) 2018-07-23
RU2428972C2 (ru) 2011-09-20
BRPI0620229A8 (pt) 2018-01-02
US8497291B2 (en) 2013-07-30
BRPI0620229A2 (pt) 2011-11-01

Similar Documents

Publication Publication Date Title
HK1126412A1 (en) Crystalline pyrimidine nucleoside derivatives suspensions in capsules
HK1120269A1 (en) Pyrimidine derivatives
GB0525080D0 (en) Pyrimidine derivatives
HK1203488A1 (en) Pyrimidine substituted purine derivatives
GB0525083D0 (en) Pyrimidine derivatives
IL181433A0 (en) Pyrimidine derivatives
IL192610A0 (en) Pyrimidine derivatives
PL1784399T3 (pl) Pochodne pirymidyny
GB0525081D0 (en) Pyrimidine derivatives
IL188725A0 (en) Pyrazine derivatives useful as adenosine receptor antagonists
GB0614579D0 (en) Pyrimidine derivatives
GB0415364D0 (en) Pyrimidine derivatives
HK1104553A1 (en) Pyrimidine derivatives
IL192002A0 (en) Antiviral nucleosides
HRP20140377T1 (en) Pyrimidine derivatives
EP1724267A4 (fr) Derive de pyrimidine
ZA200802588B (en) Imidazopyridine derivatives as A2B adenosine receptor antagonists
IL186939A0 (en) Pyrimidine derivatives and their use as
IL195018A0 (en) Piperidinyl pyrimidine derivatives
ZA201000107B (en) Pyrimidine derivatives 934
IL184779A0 (en) Novel pyrimidine nucleoside compound or salt thereof
GB0415367D0 (en) Pyrimidine derivatives
PL1951730T3 (pl) Pochodne pirymidyny połączone przez grupy heteroalkilowe
GB0505786D0 (en) A2b adenosine receptor antagonists

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20221227